INTRODUCTION
Axillary lymph node (LN) evaluation plays the most important role in staging, treatment, and prognosis of breast cancer. Therefore, axillary LN dissection (ALND) is traditionally an important part of the breast cancer therapy. [1] However, this procedure has several complications, such as numbness, pain, restriction of shoulder range of motion, and upper limb lymphedema that leads to low quality of life.
of omitting an ALND, the risk of developing an axillary recurrence in the presence of a positive SLN is <1%. With the emergence of new medicines that have remarkable effect on breast cancer treatment, adjuvant chemotherapy has gained an integral part of the therapy. In recent years, a positive effect of neoadjuvant chemotherapy (NAC) on tumor and LN downstaging as well as overall prognosis has been identified. Studies have shown axillary pathological complete response (pCR) in 20%-40% of initially node-positive patients. Thus, NAC is widely used in breast cancer therapy. SLNB could be performed before NAC and that women with involved nodes could have ALND after the completion of chemotherapy. Avoiding the possible negative effects of lymphatic scarring or uneven nodal tumor response is the advantage of this strategy. The disadvantage of this approach is that these women would need to undergo two surgeries. Nevertheless, SLNB following NAC is a contraindication as NAC can distort lymphatic drainage and reduce SLN detection rate. However, this issue is recently in doubt, and many clinical researches have been conducted in this field. [3, [5] [6] [7] The patient selection criteria, technique of mapping, type of tracer, pathologic staining, detection of involved SLN, and definition of positive SLN vary across individual literature. Thus, it is difficult to determine individual patient approach in clinical practice. There are three conditions in this subject: (1) node-negative breast cancer before and after NAC, (2) node positive before NAC that converted to node negative after NAC, and (3) node positive that does not respond to NAC and remains positive. At the present time, SLNB is a contraindication in the latest setting. It is important that the feasibility and reliability of SLNB is determined in two early items.
The aim of this study was to identify all of the clinical studies that have separately examined the results of SLNB after NAC in two subgroups, initially node negative and node positive converted to node negative, to evaluate identification rate (IR) and false-negative rate (FNR) and timing of SLNB in the context of NAC in these two subgroups.
discussion. The first and second authors were separately extracted the following predefine items: first author, year of publication, study design, sample size, country of study, clinical tumor and nodal stage, the use immunohistochemistry (IHC) on axillary nodes, mapping method of SLN, definition of pathologic complete axillary response, IR, and FNR.
The results from each successfully identification SLN was categorized as true positive, true negative or false positive, , and ≥70% were considered as mild, moderate, and severe heterogeneity, respectively. [9] P values of the Chi-square test of heterogeneity were considered as statistically significant at 0.1. Due to heterogeneity between studies, random-effects models (using the DerSimonian and Laird methods) for meta-analysis were used to calculate pooled estimates of IR and FNR with 95% confidence intervals (CIs). Potential publication bias was assessed using Egger's weighted regression tests, and the results of Egger's tests were statistically significant at P < 0.1. If there was publication bias, "trim-and-fill" method was used to adjust and correct the publication bias. [10] Subgroup analysis was performed according to the type of tracers (single/dual). Sensitivity analysis was used to assess the effect of excluding any study on the overall effect.
RESULTS

Study selection process
The articles search founded 458 studies. After removing 23 review articles and meta-analyses, 435 literature remained, and then, 399 full-text original papers were excluded (e.g., mix of before and after NAC, no data to calculate IR or FNR, no SLNB followed by ALND, SLNB before NAC, and not relevant) that resulted in 36 eligible papers. Twenty-three studies included initially node-negative cases, and 13 studies included cases of node-positive breast cancers converted to node negative after NAC. Overall, 2609 patients were enrolled: 1521 patients in the initially node-negative subgroup with a mean of 66.1 patients per studies (range: 9-320) and 1088 patients in the node positive converted to node negative after NAC subgroup with a mean of 83.6 patients per studies (range: 15-529). The studies are summarized in Table 2 . 
Percentage FNR
Nason et al. [11] 2000 USA Single Prospective 9 D, I, LS H & E, IHC 88. 8 
22.2
Tafra et al. [12] 2001 USA Multiple Prospective 29
Miller et al. [13] 2002 USA Single Retrospective 35
Vigario et al. [14] 2003 Brazil Single Prospective 37
Piato et al. [15] 2003 Brazil Single Retrospective 42 I, LS H & E 97.5 16.7
Shimazu et al. [3] 2004 Japan Single Retrospective 25
Lang et al. [16] 2004 USA Single Retrospective 30
Tanaka et al. [17] 2005 Japan Single Retrospective 17
Jones et al. [18] 2005 USA Single Retrospective 17 -
Mamounas et al. [19] 2005 USA Multiple Prospective 326
Yu et al. [20] 2007 Taiwan Single Retrospective 127 D H & E, IHC -91.3 9.6 Kinoshita [21] 2007 Japan Single Prospective 54 D, I, LS H & E -96.9 14.3 Gimbergues et al. [22] 2008 France Single Prospective 82
Papa et al. [23] 2008 Israel Single Prospective 31
Classe et al. [24] 2009 France Multiple Prospective 130 D, I
H & E, IHC 1.9 94.6 9.4
Hunt et al. [25] 2009 USA Single Retrospective 84
Cheung et al. [26] 2009 China Single Prospective 78
Pecha et al. [27] 2011 Takahashi et al. [28] 2012 Japan Single Prospective 41 D, I, LS H & E, IHC 3 87.8 5.6
Rebollo-Aguirre et al. [29] 2012 Spain Single Prospective 51 I, LS H & E, IHC, OSNA 1.7 98 9.5
Shigekawa et al. [30] 2012 Japan Single Retrospective 21
Piñero-Madrona et al. [31] 2015 Spain Multiple Prospective 49 D, I -
Kida et al. [32] 2015 
Measures of test performance of initially node negative Characteristics of included studies
In the initially node-negative subgroup, 3 studies used blue dye alone, [17, 20, 32] 4 studies used radioisotope alone, [14, 15, 22, 29] 15 studies used both blue dye and radioisotope, [3, [11] [12] [13] 16, 19, 21, [23] [24] [25] [26] [27] [28] 30, 31] and 1 study did not state the type of the tracer used. [18] One study considered abnormal palpable LNs as SLNs. [32] Concerning pathologic assessment, 6 articles used hematoxylin and eosin (H & E) only, [15] [16] [17] 21, 23, 32] 10 articles used IHC for negative H & E samples, [11] [12] [13] [14] 18, 20, 22, [24] [25] [26] 5 articles used both H & E and IHC, [3, 19, 27, 28, 30] 1 study used H & E, IHC, and one-step nucleic acid amplification (OSNA), [29] and 1 study did not state the type of the tracer used.
[31] Importantly, 1 study considered micrometastasis (yp mi) as involved SLN [20] and 3 studies considered micrometastasis (yp mi) and isolated tumor cell (ITC) (yp i+) as positive SLN. [27] [28] [29] [30] Meta-analysis The reported IR between studies ranged from 81% to 100%. Between-study heterogeneity was high and statistically significant (I 2 = 73.4%, Q-test: 82.68, P < 0.001). Due to severe heterogeneity, using random-effects meta-analysis model, the pooled IR estimated 94% (95% CI: 92%-96%).
The FNR ranged from 0% to 22%. Due to high and significant heterogeneity between studies (I 2 = 86.4%, Q-test: 161.84, P < 0.001), random-effects meta-analysis estimated the pooled FNR 7% (95% CI: 5%-9%) [ Figure 2 ].
Publication bias
Results of the Egger's test showed that there was no publication bias for IR. Results of the Egger's test showed that publication bias was existed between studies for FNR. Therefore, the Thomas et al. [34] 2011 India Single Prospective 30
Chintamani et al. [35] 2011 India Single Retrospective 15 D --100 0
Rebollo-Aguirre et al. [29] 2012 Spain Single Prospective 37 I, LS H & E, IHC, OSNA 1.7 88.7 6.7
Shigekawa et al. [30] 2012 Japan Single Retrospective 47
Takahashi et al. [28] 2012 Japan Single Prospective 46
Rebollo-Aguirre et al. [36] 2013 Kuehn et al. [37] 2013 Germany Multiple Prospective 592 D, I, LS H & E 2.7 80.1 13.5
Lee et al. [38] 2015 Yu et al. [39] 2016 Carrera et al. [40] 2016 Cao et al. [6] 2016 missing data were imputed using "trim-and-fill" method to reduce the publication bias in pooled estimates of FNR. The results of this method showed that there were six missing studies, which after imputing these studies, the corrected overall FNR was estimated 5.5% (95% CI: 2.9%-8.1%).
Subgroup analysis
Subgroup analysis according to the type of tracer showed that the pooled IR for single and dual tracers was 97% (95% CI: 95%-99%) and 91% (95% CI: 86%-94%), respectively. Moreover, the pooled FNR for single and dual tracers was 4% (95% CI: 1%-7%) and 8% (95% CI: 5%-11%), respectively.
Sensitivity analysis
Results of sensitivity analysis showed that excluding none of the studies could not change the overall FNR and IR significantly.
Measures of test performance of node-positive converted to node-negative subgroup
Characteristics of included studies
In the node-positive converted to node-negative subgroup, 3 studies used blue dye alone, [34, 35, 39] 4 studies used radioisotope alone, [29, 36, 38, 40] 6 studies used both blue dye and radioisotope, [6, 14, 33, 30, 28, 37] and 1 study also included abnormal palpable LNs as SLN. [39] Regarding pathologic assessment, 4 studies used only H & E, [6, 14, 30, 37] 2 studies performed IHC when H & E was negative, [33, 38] 4 studies used both IHE and H & E, [34, 28, 39, 40] 2 studies used OSNA, [29, 36] and 1 study did not state the type of the pathologic staining. [35] One article considered (yp mi) as involved SLN [36] and 3 articles included (yp mi) and (yp i+) as positive SLN. [6, 29, 30] 
Meta-analysis
The reported IR between studies ranged from 80.1% to 100%. Between-study heterogeneity was high and statistically significant (I 2 = 80.5%, Q-test: 71.18, P < 0.001). Due to sever heterogeneity, using random-effects meta-analysis model, the pooled IR estimated 89% (95% CI: 85%-94%).
The FNR ranged from 6.7% to 36%. Due to high and significant heterogeneity between studies (I 2 = 91.3%, Q-test: 138.54, P < 0.001), random-effects meta-analysis e s t i m a t e d t h e p o o l e d F N R 1 3 % ( 9 5 % C I : 7 % -18%) [ Figure 3 ].
Publication bias
Results of the Egger's test showed that there was no publication bias for IR. Results of the Egger's test showed that publication bias was existed between studies for FNR. Therefore, the missing data were imputed using "trim-and-fill" method to reduce the publication bias in pooled estimates of FNR. The results of this method showed that there were two missing studies, which after imputing these studies, the corrected overall FNR was estimated 10.5% (95% CI: 5.1%-15.9%).
Subgroup analysis
Subgroup analysis according to the type of tracer showed that the pooled IR for single and dual tracers was 92% (95% CI: 87%-96%) and 89% (95% CI: 80%-98%), respectively. Moreover, the pooled FNR for single and dual tracers was 9% (95% CI: 3%-15%) and 14% (95% CI: 10%-19%), respectively.
Sensitivity analysis
Sensitivity analysis showed that removing studies by Chintamani et al., [35] Kuehn et al., [37] and Cao et al. [6] can considerably change the effect of IR to 89% (95% CI: 83%-95%), 99% (95% CI: 97%-100%), and 89% (95% CI: 83%-95%), respectively. Moreover, excluding none of the studies could not change the overall FNR significantly. 
DISCUSSION
The present study analyzed literature about the feasibility and accuracy of SLNB after NAC in two subgroups of breast cancer: the initially node negative and node positive converted to node negative after NAC. IRs and FNRs were evaluated because of the most important test clinically. The most important meta-analyses related to this issue were published without regarding the node status before and after NAC, and overall results were stated. We found only one meta-analysis that refers to the node status before and after NAC, specifically initially clinically node-negative cases, which was published by Geng et al. [41] The meta-analyses in this subject are summarized in Table 3 . We think that the present meta-analysis is one of the most unique and comprehensive studies in this territory.
Based on studies of SLNB in node-negative patients with upfront surgery, IR >90% and FNR <10% have been accepted as oncologically aspect. In the patients who underwent NAC and then SLNB, these cutoff values were also considered; however, keep in mind that, these figures are arbitrary. [49, 50] In the meta-analysis established by Geng et al., [41] the pooled IR and FNR were 96% and 6%, respectively. The present study revealed pooled IR of 94% and FNR of 7% in the initially node-negative subgroup, while the pooled IR and FNR were 80.5% and 13%, respectively, in the node-positive converted to node-negative subgroup. Theoretically, chemotherapy leads to fibrosis and shrinkage and induces emboli and debris depositions in lymphatic routes that can alter lymphatic mapping and decrease IR. In addition, uneven disappear tumor burdens in LNs so as SLNs are sterilized, but non-SLNs remain involved, leading to high FNR. [29, 41, 42, 51] However, this concept has not been proved. Van der Heiden-van der Loo et al. [52] showed that there was no statistical difference between IR of SLN before or after NAC. However, it seems that IR in upfront SLNB is higher than in IR of SLNB after NAC. [18, 23, 48, 53] In a study established by Hunt et al., [25] there were no differences in FNR between upfront SLN and SLN after NAC. Furthermore, some studies in clinically node negative have revealed identical accuracy in primary SLNB and SLNB after NAC. [53, 54] The SENTINA study has shown that dual tracer increases IR. [37] The GANEA series has stated an IR of 90% with dual tracer. [24] In the NASBP-B27 study, IR was 78.1%, 88.9%, and 87.6% in blue dye alone, radioisotope alone, and in combination, respectively. [19] In the SN-FNAC trial, the use of dual tracer was associated with lower FNR. [55] The Alliance research has revealed low FNR with dual tracer. [56] Hunt et al. [25] reported lower FNR with radioisotope alone or combination of two tracers. It seems that for increasing IR and decreasing FNR, dual-tracer mapping is required. However, Geng et al. [41] concluded that there were no differences between the type of tracer mapping agents. In particular, it has been suggested that this difference may be related to the fact that the initial axillary status varied among the patients included in their study. With respect to these studies, dual tracer deems better than one.
The SENTINA and Alliance trials have resulted that for decreasing FNR <10%, at least 3 SLNs should be harvested. [37, 56] SN-FNAC study has recommended that at least 2 SLNs should be retrieved for this goal. [55] Furthermore, some studies had demonstrated a higher FNR when 1 SLN was biopsied, instead of 2 or more. [56, 57] Wong et al. [58] stated higher FNR in initially node-negative patients in whom only 1 SLN was biopsied compared to 2 or more (14.3% vs. 4.3%). The average of SLNs excised in the SENTINA, SN-FNAC, and GANEA trials were 2, 2.7, and 1.9, respectively. [24, 37, 55] Our analysis showed an average SLN dissection of 2.09 and 2.05 in the initially node-negative and node-positive converted to node-negative subgroups, respectively. In the meta-analysis conducted by Fu et al., [44] it was concluded that for decreasing FNR, both mapping and suspicious palpable LNs should be considered as SLNs. However, in our study, only 2 articles considered suspicious palpable LNs as SLNs. [33, 39] It appears that to increase IR and decrease FNR, especially in the node-positive converted to node-negative subgroup, at least 2 SLNs should be harvested and the use of dual tracer is mandatory.
In the primary SLNB without NAC, evaluation of the ITC and micrometastasis were not recommended because there was no effect on survival. However, in SLNB after NAC, ITC and micrometastasis can result from partial response and downstage of macrometastasis before NAC. [41, 43, 59] The ACOSOG Z0010 trial has concluded that IHC-detected metastases in SLNs have no influence on overall survival. [60] The SN-FNAC study has recommended that ITC and micrometastasis should be considered positive in SLN to decrease FNR in the NAC setting.
[55] Metaanalyses established by Tan et al. [46] and Geng et al. [41] have shown low FNR when IHC adds H and E stain. However, there was no consensus regarding the utility of IHC for evaluating SLN in the NAC setting. 
Number of literatures
Number of patients
Geng et al [41] 2016 16 1456
Mocellin et al [42] 2016 72 7451
Van Nijnatten et al [43] 2015 8 1395
Fu et al [44] 2014 15 2471
Fontein et al [45] 2013 40 3328
Tan et al [46] 2011 10 449
Van Deurzen et al [47] 2009 27 2148
Xing et al [48] 2006 21 1273 
CONCLUSION
There are great discrepancies between studies concerning SLNB after NAC in breast cancer. Therefore, this issue resulted in conflicting guideline recommendations. In initially node-negative patients, with regard to IR (94%) and FNR (7%) in our meta-analysis, it seems that SLNB after NAC in this group is feasible with acceptable accuracy.
In node-positive converted to node-negative patients, we did not found any meta-analysis to address this subject. Our results in this group were IR (89%) and FNR (13%) that did not reach to predefined value. Thus, SLNB after NAC in node-positive converted to node-negative patients is not recommended at this time, and novel techniques for increasing IR and decreasing FNR are required.
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